Is Pylarify approved by the FDA?

Pylarify, with the generic name piflufolastat F 18, is a diagnostic radiopharmaceutical used in conjunction with PET scans to detect prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer. Pylarify was approved by the U.S. Food and Drug Administration (FDA) on May 26, 2021. This approval marked a significant advancement in the imaging and diagnosis of prostate cancer, providing a critical tool for clinicians in managing the disease.

Uses of Pylarify

Pylarify is used specifically for:

1. Identifying Metastasis:
   • It helps detect cancer that has spread to other parts of the body in patients who are candidates for initial prostate cancer treatment.
2. Detecting Recurrence:
   • It is used in patients with suspected recurrence of prostate cancer based on elevated levels of prostate-specific antigen (PSA).

How Pylarify Works

As a radiopharmaceutical, Pylarify consists of a radioactive agent used to visualize and track biological processes in the body. When administered, it binds to PSMA, a protein often overexpressed in prostate cancer cells. This binding enables PET scans to detect the location and extent of cancer within the body.

Administration

Pylarify is administered intravenously by a healthcare professional shortly before a PET scan. Proper hydration before the scan is recommended, and patients are advised to urinate frequently following the scan to help expel the radioactive agent from the body.

Side Effects and Precautions

Common Side Effects:

• Change in taste
• Headache
• Loss of taste
• Unusual tiredness or weakness

Serious Side Effects:

• Difficulty breathing or swallowing
• Fast heartbeat
• Skin itching, rash, or redness
• Swelling of the face, throat, or tongue

Warnings:

• Pylarify exposure involves radiation, which may increase the risk of cancer. Patients should discuss these risks with their healthcare provider.

Precautions

• Allergies: Inform your doctor of any allergies to medications, foods, dyes, or animals.
• Pediatric Use: The safety and efficacy in pediatric patients have not been established.
• Geriatric Use: No geriatric-specific limitations have been found.
• Breastfeeding: Women should weigh the benefits and risks before using Pylarify while breastfeeding.

Conclusion

Pylarify represents a significant advancement in the diagnostic imaging of prostate cancer. Its ability to precisely detect PSMA-positive lesions aids in the accurate assessment of cancer spread and recurrence, making it a vital tool for clinicians managing prostate cancer. Despite its benefits, it is essential to consider the potential risks and side effects associated with its use.

How to obtain the latest development progress of all drugs?

In the Synapse database, you can stay updated on the latest research and development advances of all drugs. This service is accessible anytime and anywhere, with updates available daily or weekly. Use the "Set Alert" function to stay informed. Click on the image below to embark on a brand new journey of drug discovery!